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Chemerin15 inhibits neutrophil-mediated vascular
inflammation and myocardial ischemia-reperfusion
injury through ChemR23
Jenna L. Cashw+, Stefania Bena*, Sarah E. Headland*, Simon McArthur, Vincenzo Brancaleone
& Mauro Perretti
William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, London
Neutrophil activation and adhesion must be tightly controlled to
prevent complications associated with excessive inflammatory
responses. The role of the anti-inflammatory peptide chemerin15
(C15) and the receptor ChemR23 in neutrophil physiology is
unknown. Here, we report that ChemR23 is expressed in
neutrophil granules and rapidly upregulated upon neutrophil
activation. C15 inhibits integrin activation and clustering,
reducing neutrophil adhesion and chemotaxis in vitro. In the
inflamed microvasculature, C15 rapidly modulates neutrophil
physiology inducing adherent cell detachment from the inflamed
endothelium, while reducing neutrophil recruitment and heart
damage in a murine myocardial infarction model. These effects
are mediated through ChemR23. We identify the C15/ChemR23
pathway as a new regulator and thus therapeutic target in
neutrophil-driven pathologies.
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INTRODUCTION
In vertebrates, tissue trauma, infection and ischaemia–reperfusion
injury prompt rapid neutrophil extravasation from the circulation
to the site of injury [1]. Neutrophil trafficking follows a multi-step
cascade of leukocyte–endothelial interactions initiated upon
capture of the circulating cell by selectins. Neutrophil rolling,
also mediated by selectins, follows, enabling the leukocyte to
interact with chemokines exposed on the endothelium. Inside-out
signalling triggered by these chemokines or cytokines leads to
neutrophil b2 integrin activation, which involves a conformation
change from a bent, low affinity form to an extended, high affinity
conformation. Integrin pro-adhesive activity can also be increased
by clustering, whereby the integrin accumulates in discrete areas
of the plasma membrane [2]. Interaction of these activated b2
integrins with their respective ligands results in neutrophil
adhesion, followed by intravascular crawling. Neutrophils then
undergo transendothelial migration and move along chemotactic
gradients towards the inflammatory site [3,4].
Knockout mice, neutralizing antibodies and the existence of
pathological conditions such as leukocyte adhesion deficiency,
have underlined the importance of integrins, integrin activation
and CD62L (L-selectin) in neutrophil recruitment [4,5]. Excessive
intravascular neutrophil recruitment and ensuing activation is a
key pathogenic feature of numerous vascular diseases, including
ischaemia–reperfusion injury; for example, post-myocardial
infarction [6] and atherosclerosis [7]. It is clear that a delicate
balance must exist to ensure effective removal of the inciting
inflammatory insult, while avoiding overly aggressive or pro-
longed inflammatory responses that are detrimental to the host.
However, little information exists regarding inhibitors of neutrophil
integrin activation and thus recruitment during inflammation.
Higher organisms have evolved a network of anti-inflammatory
and pro-resolving pathways, which counter-regulate inflam-
matory responses and promote regain of tissue homeostasis, ensuring
that the inflammatory response is limited in magnitude, time
and space. Improved understanding of these endogenous regulatory
systems could pave the way for the development of therapeutic
approaches to tame inflammatory pathologies [8,9]. Recently, we
identified a novel pathway for inflammatory resolution, whereby
chemerin15 (C15), a 15-aa peptide derived from the chemoattractant
protein chemerin, inhibits pro-inflammatory mediator production by
macrophages and promote phagocytosis of apoptotic cells through
the receptor ChemR23 [10,11].
ChemR23 was originally detected on monocytes, macrophages
and dendritic cells [12,13]; however, granulocyte expression has
not been investigated. In the present study, we provide the first
compelling evidence that ChemR23 is expressed on neutrophils
and can be harnessed by the pro-resolving peptide C15 to restrict
excessive neutrophil trafficking to inflammatory loci, including in
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a murine myocardial infarct model. C15 appears to achieve
these effects by fine-tuning neutrophil–endothelial cell inter-
actions through modulation of b2 integrin activation (affinity) and
clustering (avidity) and L-selectin shedding.
RESULTS
ChemR23 is rapidly upregulated on neutrophils
Previous studies have focused on the role of chemerin and its
receptor ChemR23 on dendritic cells, monocytes and macro-
phages [10–13], revealing important modulatory actions. Using
flow cytometry we found that ChemR23 is also expressed on 68%
of resting human neutrophils (Fig 1A,B). Neutrophil ChemR23
expression rapidly increased upon stimulation with pro-inflam-
matory mediators, tumor necrosis factor alpha (TNFa), fMLF and
interleukin-8 or exposure of isolated neutrophils to activated
endothelial cells under flow, but was unaffected by anti-
inflammatory mediators (annexin A1; a-melanocyte-stimulating
hormone; or C15; Fig 1A–C). We also demonstrate that ChemR23
is expressed on circulating murine neutrophils from wild-type but
not ChemR23 / mice (Fig 1D). As ChemR23 surface expression
is upregulated within minutes, we suspected expression within
neutrophil granules which can undergo rapid mobilization to fuse
with the cells plasma membrane. Congruently, immunofluores-
cence studies revealed punctate intracellular ChemR23 expression
on resting human neutrophils, a distribution, which became
polarized upon cell activation with TNFa (Fig 1E). Staining for
neutrophil granule markers suggests ChemR23 colocalization with
neutrophil secretory vesicle marker CD35 and specific granule
marker CD66b, but not azurophil granule marker CD63 (Fig 1F).
Rapid modulation of ChemR23 expression through degranulation,
as shown for the pro-resolving mediator annexin A1, could
provide a mechanism to quickly alter neutrophil phenotype, even
in the vasculature, allowing the cell to perceive and respond to
signals from the environment in a manner that is dependent upon
the particular vesicles or granules mobilized [14].
As neutrophil ChemR23 expression has not been documented
before, we sought to verify the presence of the functional GPCR
using calcium mobilization assays. C15 and chemerin, but
not C15-S (scrambled C15 peptide), induced calcium flux
responses in human neutrophils, which could be inhibited
with the ChemR23 antagonist CCX2005 (Fig 1G). The expression
of functional ChemR23 on human and murine neutrophils
opens the possibility that ChemR23 ligands could directly
modulate neutrophil reactivity.
Chemerin15 selectively modulates neutrophil physiology
To assess the potential impact of C15 on neutrophil physiology,
we investigated its effect on CD62L (L-selectin) and PSGL-1, which
are implicated in mediating neutrophil rolling on the vascular
endothelium. In particular, CD62L shedding results in higher
neutrophil rolling velocities and is thought to reduce its cross-
linking thus limiting neutrophil b2 integrin activation [15,16].
Treatment of human resting neutrophils with 10 pM C15 resulted
in 50% shedding of CD62L and a 25% reduction in PSGL-1
expression (Fig 2A, supplementary Fig S1A online), suggesting that
C15 might have a role in regulating neutrophil rolling events.
Other anti-inflammatory molecules known to suppress neutrophil
activation and induce L-selectin shedding are annexin A1 and
non-steroidal anti-inflammatory drugs [17,18].
We next determined the effect of C15 on b2 integrin activation
and clustering, which are key events in increasing the
pro-adhesive activity of the integrin and thus are critical to neutro-
phil adhesion, intravascular crawling and extravasation. Integrin
activation can be assessed using antibodies that specifically
detect the extended high affinity conformation of the integrin.
Neutrophil pre-treatment with C15 prior to stimulation with
TNFa led to significant inhibition of CD18 (60%), CD11b (75%)
and CD11a (58%) activation (Fig 2B, supplementary Fig S1B
online). However, C15 was unable to modulate total CD11b
levels (supplementary Fig S2A online) or neutrophil degranulation
(supplementary Fig S2B online), indicating that C15 specifically
interferes with integrin activation rather than degranulation-
mediated upregulation of integrin expression. We next assessed
the effect of C15 on CD11a and CD11b clustering (avidity),
whereby integrin can accumulate in discrete areas of the
plasma membrane [2]. Using fluorescence microscopy, we
found that the relatively dispersed distribution of CD11a and
CD11b in vehicle-treated neutrophils became much more
clustered upon TNFa treatment and that this response was
profoundly reduced by C15 (Fig 2C).
We next assessed whether the observed effects of C15 on
integrin activation and clustering could affect neutrophil binding
and adhesion to the b2 integrin ligand ICAM-1. Indeed, we found
that C15 inhibits human neutrophil adhesion and spreading to
immobilized ICAM-1 by 65% (Fig 2D, representative micrographs
in Fig 2F). Furthermore, ChemR23 antagonism using CCX2005
(100 nM) significantly attenuated C15-elicited suppression of
ICAM-1 adhesion (Fig 2E,F) and CD11b activation (Fig 2G). In
agreement with these results, wild-type but not ChemR23 /
murine neutrophils treated with C15 show marked reduction in
binding of soluble ICAM-1-Fc chimeric protein (Fig 2H).
To determine whether C15 can regulate integrin-dependent
neutrophil chemotaxis in vitro, we used live cell tracking of
neutrophils adherent to ICAM-1-coated IBIDI m-slides and then
treated with C15 in the presence of a fMLF gradient. C15
significantly impaired neutrophil chemotaxis (representative plots
shown in Fig 2I), quantified by measuring centre of mass (spatial
averaged point of all cell endpoints) an indicator of cell
directionality and velocity (Fig 2J).
In the above assays, we have focused on the effect of C15 on
neutrophil b2 integrin activation and downstream events as the
role of b2 integrins in neutrophil physiology and neutrophil-driven
inflammatory pathologies is widely appreciated. However,
neutrophils also express b1 integrin (CD29 [19]) which, though
less extensively elucidated, also appears to have a role in
mediating neutrophil adhesion. We found that C15 suppresses
b1 integrin activation (supplementary Fig S3A online) and
adhesion to b1 integrin ligand fibronectin in wild-type but not
ChemR23 / neutrophils (supplementary Fig S3B online). C15
also inhibits b2 and b1 integrin activation on other ChemR23þ
cell types (for example, monocytes; supplementary Fig S4A,B
online) and induced by other ligands (for example, fMLF;
supplementary Fig S4C online) suggesting that to some extent
the effects of C15 on integrin activation are independent of
integrin subtype, cell type (providing ChemR23 is expressed) and
integrin activator. C15 might achieve these effects by impinging
on a common component of the inside-out signalling pathway
that elicits integrin activation.
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Fig 1 | Non-genomic modulation of ChemR23 expression on neutrophils (A,B) ChemR23 expression on human leukocytes was determined by flow
cytometry on vehicle and TNFa (10 ng/ml; 20min)-stimulated cells. Representative histograms shown in A. (C) Neutrophils were treated with vehicle,
pro-inflammatory (TNFa; fMLF, 1mM; IL-8, 100 ng/ml) or anti-inflammatory mediators (annexin A1, 10 nM; aMSH, 10 nM; C15, 10 pM) followed by
staining for ChemR23. ChemR23 expression was also assessed on isolated human neutrophils before and after flow over activated endothelial cells.
(D) ChemR23 expression by wild-type but not ChemR23 / murine neutrophils. (E) Permeabilized human neutrophils were stained with anti-
ChemR23 (with goat-anti-mouse Alexa 488 secondary) and wheat germ agglutinin (WGA-Alexa 647) to visualize the cell membrane. Cells were
analysed by confocal microscopy. (F) Human neutrophils were stained for ChemR23 and markers of secretory vesicles (CD35), specific granules
(CD66b) and azurophil granules (CD63). (G) Neutrophils were loaded with Fura2-AM and calcium flux responses elicited by control (ionomycin),
vehicle, ChemR23 inhibitor (CCX2005, 100 nM), C15 (10 pM), scrambled C15 (C15-S; 10 pM) or chemerin (1 nM). Responses are displayed as DF340/
F380. Graphs show mean values±s.e.m. from three to six independent experiments. *Po0.05 relative to vehicle-treated or pre-flow cells. aMSH,
alpha-melanocyte-stimulating hormone; IL-8, interleukin-8; TNFa, tumour necrosis factor alpha.
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We therefore assessed the effect of C15 on common compo-
nents of inside-out signalling leading to b2 integrin activation and
clustering, Syk, Erk and Src kinases [20–24]. We used an intra-
cellular flow cytometry approach to assess the phosphorylation
status of these enzymes. pSyk (Y525/526) and pERK (Y202/204)
represent activated enzymes while de-phosphorylation of Y527 of
Src results in its activation. Neutrophil stimulation with TNFa
activated all three enzymes, whereas neutrophil pre-treatment
with 10 pM C15 prevented TNFa-induced activation of Syk (69%),
ERK (80%) and Src (61%; Fig 2K).
Collectively, these data indicate that C15 engages ChemR23,
inhibits neutrophil adhesion and chemotaxis by interfering
with integrin activation and clustering by impinging on common
components of the inside-out signalling pathway, thus affecting
Fig 2 | C15 peptide selectively modulates neutrophil physiology through ChemR23 (A) Cells were treated with C15 (0.1–1,000 pM, 20min), stained with
anti-CD62L and anti-PSGL-1 and marker expression analysed by flow cytometry. (B) Cells were treated with C15 (0.1–1,000 pM, 10min) and then
stimulated with TNFa (10 ng/ml, 20min). Cells were stained for activated b2 integrins; CD18, CD11b and CD11a and expression analysed by flow
cytometry. (C) Cells were treated with vehicle or C15 (10 pM, 10min) and then stimulated with TNFa (10min). Integrin clustering was assessed by
staining cells for CD11a and CD11b and analysing distribution by fluorescence microscopy. (D) Cells were treated with vehicle or C15 (10 pM, 10min)
and allowed to adhere to ICAM-1-coated multispot slides in the presence of TNFa for 10min in static conditions. (E) Effect of ChemR23 antagonist
(CCX2005) on C15-mediated inhibition of neutrophil static adhesion. (F) Representative micrographs of static adhesion assay are shown. (G) Effect of
ChemR23 antagonist on C15-mediated inhibition of CD11b activation. (H) Wild-type and ChemR23 / mouse neutrophils were pre-treated with
vehicle or C15 (10 pM) followed by exposure to soluble ICAM-1-Fc in the presence or absence of TNFa for 1, 5, 10 or 20min. ICAM-1 binding was
quantified by staining with F’ab-FITC and analysing by flow cytometry. (I) Human neutrophils were pre-treated with vehicle or C15 (100 pM) then
allowed to adhere to ICAM-1-coated IBIDI m-slides. Chemotaxis towards fMLF was then monitored in real time over 30min. Representative trajectory
paths of 30 randomly chosen cells are shown. Red paths indicate rightward movement and black paths leftward movement. (J) Quantification of
integrin-dependent neutrophil chemotaxis. Centre of mass (spatial averaged point of all cell endpoints) and velocity. (K) Neutrophils were pre-treated
with C15 (10 pM) or vehicle prior to administration of vehicle or TNFa (10min). Intracellular signalling flow cytometry was then performed following
staining for pErk, pSyk and pSrc. Data are expressed as means±s.e.m. from four to seven independent experiments; *Po0.05; **Po0.01; ***Po0.001
relative to TNFa or fMLF-treated cells (D,E,G,H,J,K) or vehicle-treated cells (C) unless otherwise noted. C15, chemerin 15; FOV, field of view. ICAM,
intracellular adhesion molecule; TNFa, tumour necrosis factor alpha.
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downstream b2-integrin-ICAM-1 interactions. Coupled to
modulation of L-selectin shedding, these results suggest that C15
could regulate neutrophil–endothelial cell interactions under
shear conditions.
C15 inhibits human neutrophil–endothelial interactions
We used a parallel-plate flow chamber assay to study the impact of
C15 on neutrophil–endothelial cell interactions under flow. C15
treatment of unstimulated neutrophils reduced cell rolling and
adhesion with no significant alterations in transmigration,
resulting in 450% reduction in total neutrophil–endothelial
cell interactions (Fig 3A). As expected, TNFa-activated neutrophils
showed reduced rolling and elevated adhesion and transmigration
events versus vehicle-treated neutrophils. In this context, C15
administration decreased neutrophil adhesion and transmigration
by up to 100% with a corresponding increase in rolling
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events (Fig 3B). However, C15 was unable to modulate endothelial
cell physiology to impact neutrophil arrest and transmigration
(supplementary Fig S5 online). Collectively, we demonstrate
that C15 directly targets neutrophils, particularly once in an
activated state, to modulate their interactions with inflamed
endothelial cells.
C15 inhibits microvascular inflammation through ChemR23
To assess whether the effects of C15 on human and murine
neutrophils in vitro are relevant in the context of vascular
inflammation, we performed intravital microscopy of the inflamed
mesenteric microcirculation. We administered TNFa, which
promotes microvascular inflammation by direct activation of
blood-borne neutrophils [25].
TNFa administration reduced leukocyte rolling velocities in
mesenteric post-capillary venules, with concomitant increases
in leukocyte adhesion (ninefold) and transmigration (sevenfold) at
the optimal 2 h time point (Fig 4A–D). C15 (10 pg/mouse,
intraperitoneal) administration 30min prior to TNFa challenge
counteracted the effects of this pro-inflammatory cytokine,
resulting in elevated leukocyte rolling velocities (fourfold increase)
and reduced neutrophil adhesion (70%) and extravasation
(60%; Fig 4C; representative images shown in Fig 4B). C15
elicited these effects in a concentration-dependent manner, with
maximal efficacy with as little as 10 pg or 100 pg/mouse (Fig 4C).
Time-course analyses revealed that C15 accelerated the return
to baseline rolling velocities while reducing neutrophil adhesion
and emigration (Fig 4D).
In order to visualize a direct effect of C15 on on-going
intravascular neutrophil recruitment, a situation of greater
relevance to the treatment of inflammatory pathologies such as
vascular injury in the clinic, we applied a real-time intravital
protocol. TNFa-inflamed vessels were monitored for 10min
following intravenous administration of either saline or C15 peptide
(10 pg/mouse; Fig 4E–G). In this context, C15, but not vehicle,
elicited a rapid detachment of B50% adherent neutrophils from
the inflamed venular endothelium on average 3.4 min following
C15 injection (Fig 4F; representative venules shown in Fig 4G).
The functional involvement of ChemR23 in these in vivo proper-
ties of C15 was determined using ChemR23 / mice. In these
animals, pre-treatment with C15 peptide was unable to modulate
neutrophil rolling velocities, adhesion and transmigration in the
inflamed microcirculation (Fig 4H). The pivotal role for endogenous
ChemR23 was equally evident in the real-time protocol, with an
abrogation of C15-induced neutrophil detachment in ChemR23 /
mesenteric venules (Fig 4I). Collectively, these data demonstrate
the ability of the chemerin-derived peptide, C15 to modulate
neutrophil–endothelial interactions when administered prior to as
well as during on-going vascular inflammation through ChemR23.
We next employed a murine model of acute myocardial
infarction (AMI) to assess the relevance of the C15/ChemR23
pathway in neutrophil physiology in a clinically relevant disease
model where neutrophil recruitment and b2 integrins are key
pathogenic determinants [6,26,27]. As expected, AMI mouse
hearts showed high myeloperoxidase activity (indicative of
neutrophil infiltration) and elevated levels of Troponin-I a
marker of myocardial damage used in the clinic [28]. Treatment
with C15 peptide prior to AMI significantly inhibited both
neutrophil myocardial infiltration and heart damage, protective
effects that could be abrogated using a ChemR23 inhibitor (Fig 4J).
The data we report here for C15 provide, to our knowledge, the
first description of a pro-resolving pathway that modulates
neutrophil-dominated vascular inflammation in part through in-
hibition of integrin activation. We thus identify the C15/ChemR23
axis as a novel therapeutic target in the treatment and/or
prevention of vascular inflammation and injury. On this vein, it
is tempting to propose that better understanding of how ChemR23
can be tuned towards anti-inflammatory functions could guide
novel approaches for therapeutic control of aberrant neutrophil
activation in disease. Further studies could address whether C15
can be used as the starting backbone for novel therapeutics,
particularly for application as therapeutics in vasculitides
and other forms of intravascular neutrophil activation such as
reperfusion injury post-myocardial infarction or cardiac surgery.
METHODS
Unless otherwise stated, reagents were sourced from Sigma
Aldrich (Gillingham, UK).
Chemerin peptides. C15 (AGEDPHGYFLPGQFA) and scrambled
C15 (C15-S, GLFHDQAGPPAGYEF) were synthesized by
Biosynthesis (Lewisville, TX, USA), reconstituted (1mM in
PBSþ 0.1% BSA) and stored at  80 1C for up to 6 months.
Peptide was diluted from fresh aliquots for each experiment.
Fig 4 | Chemerin15 peptide inhibits neutrophil recruitment in the inflamed vasculature and in myocardial infarction model through ChemR23
(A) Experimental scheme for prophylactic C15 administration. Briefly, C15 (0.1–100 pg/mouse) or vehicle (PBS) were delivered i.p., followed
by i.p. TNFa (500 ng) 30min later. Preparation of the mesentery was performed 2 h post-TNFa injection for visualization of its microcirculation.
(B) Representative images of the 2-h time point. (C) Dose response to C15 (0.1–100 pg/mouse). (D) Time course (0–4 h) to optimal 10 pg/mouse C15
dose. (A–D) Extent of vascular inflammation was quantified by measuring leukocyte rolling velocities (VWBC, mm/s), adhesion and transmigration
events in 3–6 post-capillary venules per mouse. (E) Experimental scheme for therapeutic C15 administration. (F) TNFa (500 ng) was administered i.p.
followed by surgery 2 h later. Once a representative vessel was located, C15 (10 pg) or vehicle was administered i.v. and adherent cells monitored
over 10min. (G) Representative images are shown of 0- and 10-min time points. (H) Effect of prophylactic C15 administration on microvascular
inflammation in wild-type and ChemR23 / animals. (I) Effect of therapeutic C15 administration on leukocyte detachment in wild-type and
ChemR23 / animals. (J) Myocardial ischaemia–reperfusion injury (30-min ischaemia: 2-h reperfusion) was performed to model myocardial infarct.
ChemR23 antagonist CCX832 (2mg/mouse) or vehicle were delivered s.c. 24 h and immediately prior to surgery. C15 (100 pg/mouse) or vehicle were
delivered i.v. at the start of surgery. MPO activity and plasma Troponin-I were quantified as measures of neutrophil recruitment and heart damage.
Data are expressed as means±s.e.m. for three to eight mice per treatment group. *Po0.05; **Po0.01; ***Po0.001 relative to TNFa-treated or AMI
animals (C,D,H,J) or relative to vehicle-treated animals (I,F) unless otherwise noted. i.p., intraperitoneal, i.v., intravenous; ns, not significant; PBS,
phosphate-buffered saline; s.c., subcutaneous; TNFa, tumour necrosis factor alpha; Veh; vehicle.
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In vitro methods, Neutrophil isolation. Neutrophils were isolated
from human whole blood using histopaque 1,077 and 11,191,
as previously described [29].
ChemR23 staining for flow cytometry and immunofluorescence.
For determination of ChemR23 expression on human leukocytes
initial experiments used two different anti-ChemR23 antibodies
MAB362 (R&D Systems, Abingdon, UK; clone 84939) and clone
4C7 (gift of Prof M. Parmentier, Bruxelles, Belgium). Low
ChemR23 expression was evident on resting neutrophils using
both 4C7 and MAB362 and the commercially available MAB362
was used in all subsequent experiments (10 mg/ml). Full details can
be found in the supplementary Methods online.. See supplemen-
tary Methods online for whole blood flow cytometry, neutrophil
chemotaxis assays, phospho flow cytometry, ICAM-1-Fc binding,
static ICAM-1 adhesion, static fibronectin adhesion, integrin
clustering and flow chamber assays.
In vivo methods intravital microscopy. C57Bl/6J mice were
sourced from Charles River (Margate, UK), whereas Sv129Ev
wild-type and ChemR23 / mice were provided by Takeda
Pharmaceuticals (Cambridge, UK). Intravital microscopy was
performed as previously described, see [29] and supplementary
Methods online.
Real-time neutrophil detachment assays. The jugular vein of
anaesthetized mice was cannulated and the mesenteric vascular
bed exteriorized 2 h post 500 ng intraperitoneal TNFa injection.
Post-capillary venules (20–40 mm diameter) were selected and
either sterile saline (100 ml) or C15 (100 ml; 0.3 ng/kg) given
intravenous. Vessels were recorded for 2min before and 10min
after intravenous injection for offline analysis. Number of adherent
neutrophils were quantified every 2min (see supplemental
Methods online for description of intravital microscopy protocol).
Murine myocardial infarction model (ischaemia–reperfusion
injury). See supplementary Methods online for description.
Statistics. Student’s t-test and one-way ANOVA (with
Bonferroni’s post hoc test) were performed using GraphPad
Prism 5.0 software.
Supplementary information is available at EMBO reports online
(http://www.emboreports.org).
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